Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imatinib in Idiopathic Hypereosinophilic Syndrome
NCT00171860Phase 2Terminated
- Sponsor
- Novartis
- Start
- Sep 2002
- Primary completion
- Jul 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of imatinib in idiopathic hypereosinophilic syndrome (HES), sponsored by Novartis. Primary endpoint: Rate of complete and partial response and relapse. Started Sep 2002; status: terminated.
02
Drugs
03
Conditions
idiopathic hypereosinophilic syndrome (HES)
Beyond the preview
Go deeper on NCT00171860.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00171860.